Lirafugratinib (RLY-4008) is a selective FGFR2 inhibitor with oral activity.

 

Brand: BCM

 

Target: FGFR

 

Signaling Pathways: Angiogenesis; Tyrosine Kinase/Adaptors

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

Isomeric SMILES: CC1=NC(=NC=C1)OC2=C(C=C(C=C2)C3=C(N(C4=NC=NC(=C34)N)C)C5=CC=C(C=C5)NC(=O)C(=C)C)F  

 

InChIKey: XOQVZSSDIQQUGO-UHFFFAOYSA-N  

 

InChI: InChI=1S/C28H24FN7O2/c1-15(2)27(37)35-19-8-5-17(6-9-19)24-22(23-25(30)32-14-33-26(23)36(24)4)18-7-10-21(20(29)13-18)38-28-31-12-11-16(3)34-28/h5-14H,1H2,2-4H3,(H,35,37)(H2,30,32,33)

 

Attribute
[Chem Name]	N-[4-[4-amino-5-[3-fluoro-4-(4-methylpyrimidin-2-yl)oxyphenyl]-7-methylpyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methylprop-2-enamide
[Synonym]	Lirafugratinib; RLY-4008
[CAS No.]	2549174-42-5
[Formula]	C28H24FN7O2
[Molecular]	509.55
[Form]	Solid Powder
[Storage]	Store at -20°C

Goods Tag